このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Pluri マネジメント

マネジメント基準チェック /14

Pluri'sの CEO はYaky Yanayで、 Feb2014年に任命され、の在任期間は 10.33年です。の年間総報酬は$ 2.75Mで、 15.1%給与と84.9%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の3.07%を直接所有しており、その価値は$ 902.47K 。経営陣と取締役会の平均在任期間はそれぞれ3.3年と2.3年です。

主要情報

Yaky Yanay

最高経営責任者

US$2.7m

報酬総額

CEO給与比率	15.1%
CEO在任期間	10.3yrs
CEOの所有権	3.1%
経営陣の平均在職期間	3.3yrs
取締役会の平均在任期間	2.3yrs

経営陣の近況

Recent updates

Pluri gains as PROTO project receives €7.5M EU grant

Sep 06

Pluristem Therapeutics renames as Pluri

Jul 25

Pluristem Therapeutics (NASDAQ:PSTI) Has Debt But No Earnings; Should You Worry?

Dec 04

We Think Pluristem Therapeutics (NASDAQ:PSTI) Needs To Drive Business Growth Carefully

Aug 18

What Is The Ownership Structure Like For Pluristem Therapeutics Inc. (NASDAQ:PSTI)?

Mar 15

We're Hopeful That Pluristem Therapeutics (NASDAQ:PSTI) Will Use Its Cash Wisely

Feb 08

CEO報酬分析

Pluri の収益と比較して、Yaky Yanay の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	-US$22m
Dec 31 2023	n/a	n/a	-US$24m
Sep 30 2023	n/a	n/a	-US$27m
Jun 30 2023	US$3m	US$414k	-US$28m
Mar 31 2023	n/a	n/a	-US$31m
Dec 31 2022	n/a	n/a	-US$33m
Sep 30 2022	n/a	n/a	-US$36m
Jun 30 2022	US$1m	US$489k	-US$41m
Mar 31 2022	n/a	n/a	-US$47m
Dec 31 2021	n/a	n/a	-US$51m
Sep 30 2021	n/a	n/a	-US$53m
Jun 30 2021	US$9m	US$453k	-US$50m
Mar 31 2021	n/a	n/a	-US$43m
Dec 31 2020	n/a	n/a	-US$37m
Sep 30 2020	n/a	n/a	-US$31m
Jun 30 2020	US$350k	US$303k	-US$29m
Mar 31 2020	n/a	n/a	-US$29m
Dec 31 2019	n/a	n/a	-US$31m
Sep 30 2019	n/a	n/a	-US$34m
Jun 30 2019	US$887k	US$373k	-US$35m
Mar 31 2019	n/a	n/a	-US$37m
Dec 31 2018	n/a	n/a	-US$28m
Sep 30 2018	n/a	n/a	-US$28m
Jun 30 2018	US$443k	US$393k	-US$26m
Mar 31 2018	n/a	n/a	-US$24m
Dec 31 2017	n/a	n/a	-US$30m
Sep 30 2017	n/a	n/a	-US$29m
Jun 30 2017	US$3m	US$253k	-US$28m

報酬と市場: Yakyの総報酬 ($USD 2.75M ) は、 US市場 ($USD 673.68K ) の同規模の企業の平均を上回っています。

報酬と収益: Yakyの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Yaky Yanay (53 yo)

10.3yrs

在職期間

US$2,745,573

報酬

Mr. Yaacov Yanay, also known as Yaky, is the Co-Founder of the EyeCue Vision Technologies Ltd. Mr. Yanay has been Chief Executive Officer of Pluri Inc. (formerly Pluristem Therapeutics, Inc.) since June 23...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Yaacov Yanay	President	10.3yrs	US$2.75m	3.07% $ 844.5k
Chen Franco-Yehuda	CFO, Treasurer & Secretary	5.3yrs	US$375.24k	0.36% $ 99.4k
Lior Raviv	Chief Technology Officer	2.5yrs	データなし	データなし
Efrat Livne-Hadass	Chief Wellbeing Officer	no data	データなし	データなし
Nitsan Halevy	Chief Medical Officer	3.3yrs	データなし	データなし
Nimrod Bar Zvi	Chief Commercial Officer	2.4yrs	データなし	データなし

3.3yrs

平均在職期間

経験豊富な経営陣: PLURの経営陣は経験豊富であると考えられます ( 3.3年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Yaacov Yanay	President	9.3yrs	US$2.75m	3.07% $ 844.5k
Doron Birger	Independent Director	2.9yrs	US$45.42k	0.043% $ 11.9k
Zami Aberman	Chairman	18.6yrs	US$123.69k	2.45% $ 674.5k
James Roosevelt	Member of Advisory Board	less than a year	データなし	データなし
Lorne Abony	Independent Director	less than a year	データなし	0.011% $ 2.9k
Yoram Palti	Member of Strategic Advisory Board	2.3yrs	データなし	データなし
Eilon Tirosh	Member of Strategic Advisory Board	2.3yrs	データなし	データなし
Richard Kendall	Member of Scientific Advisory Board	less than a year	データなし	データなし
Maital Shemesh-Rasmussen	Independent Director	3yrs	US$44.00k	0.049% $ 13.4k
Prasad Adusumilli	Member of Scientific Advisory Board	less than a year	データなし	データなし
Rami Levi	Independent Director	3yrs	US$40.75k	0.048% $ 13.3k

2.3yrs

平均在職期間

70yo

平均年齢

経験豊富なボード: PLURの取締役会は経験豊富ではない ( 2.3年の平均在任期間) ため、新しい取締役会が必要であると考えられます。

Pluri マネジメント

マネジメント 基準チェック /14

主要情報

経営陣の近況

Pluri Inc., Annual General Meeting, Jun 25, 2024

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division

Pluri Inc. Announces Appointment of Lorne Abony to Board of Directors

High number of new and inexperienced directors

Pluristem Therapeutics Inc. Announces Board Changes

Recent updates

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri Inc.’s PLX-R18 Acute Radiation Syndrome Contract

Pluri Receives Deficiency Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement for Continued Listing on the Nasdaq Capital Market

Third quarter 2024 earnings released: US$1.01 loss per share (vs US$1.53 loss in 3Q 2023)

Pluri Inc., Annual General Meeting, Jun 25, 2024

New minor risk - Shareholder dilution

Pluri Inc. Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Pluri Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Second quarter 2024 earnings released: US$0.12 loss per share (vs US$0.24 loss in 2Q 2023)

Pluri Inc. Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

Pluri Inc. Appoints Andy Lewin to Lead Business of its Contract Development and Manufacturing Organization: PluriCDMO Division

First quarter 2024 earnings released: US$0.12 loss per share (vs US$0.19 loss in 1Q 2023)

Pluri Receives an Extension of an Additional 180 Calendar Days from The Nasdaq Stock Market LLC to Regain Compliance with the Minimum Bid Price Requirement

Full year 2023 earnings released: US$0.77 loss per share (vs US$1.28 loss in FY 2022)

Pluri Inc. Announces PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in Phase I Study: Results Published in Nature Bone Marrow Transplantation

Pluri Inc. Announces Appointment of Lorne Abony to Board of Directors

Pluri Inc. announced that it has received $8.469323 million in funding

Pluri Inc. announced that it expects to receive $8.170972 million in funding

Price target decreased to US$7.00

High number of new and inexperienced directors

Pluri Receives Non-Compliance Letter from Nasdaq

Pluri Inc. Announces €7.5 Million Non-Dilutive Grant from the European Union’s Horizon Europe Program to Study PLX-PAD Cells for Osteoarthritis Treatment

Pluri gains as PROTO project receives €7.5M EU grant

Pluristem Therapeutics renames as Pluri

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Pluristem Therapeutics Inc. Announces Board Changes

Price target increased to US$9.75

High number of new directors

Price target increased to US$9.75

High number of new directors

Pluristem Therapeutics Inc. and Tnuva Group Appoint Eyal Rosenthal as Chief Executive Officer of Their New Joint Venture

High number of new directors

Chairman recently bought US$145k worth of stock

Pluristem Therapeutics Inc. Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19

Price target decreased to US$7.75

Pluristem Therapeutics (NASDAQ:PSTI) Has Debt But No Earnings; Should You Worry?

We Think Pluristem Therapeutics (NASDAQ:PSTI) Needs To Drive Business Growth Carefully

Independent Director Isaac Braun has left the company

Insider recently sold US$1.6m worth of stock

Insider recently sold US$102k worth of stock

Pluristem Reports Positive Topline Phase I Results in Innovative Hematology Program, Which Is First to Study PLX-R18 in humans

What Is The Ownership Structure Like For Pluristem Therapeutics Inc. (NASDAQ:PSTI)?

New 90-day low: US$5.58

Earnings beat expectations

We're Hopeful That Pluristem Therapeutics (NASDAQ:PSTI) Will Use Its Cash Wisely

Pluristem Therapeutics launches $30M registered direct offering

Pluristem Therapeutics Inc. Announces Board Appointments

Have Insiders Been Buying Pluristem Therapeutics Inc. (NASDAQ:PSTI) Shares?

Pluristem Therapeutics Inc. Enters Collaboration With Innovare R&D to Expand Its ARDS Associated With COVID-19 Program to Mexico

Pluristem expands COVID-19 program in Mexico

Price target lowered to US$8.50

Pluristem Therapeutics Inc. Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study

Pluristem - Moment Of Truth

New 90-day high: US$11.40

Insider recently bought US$194k worth of stock

Market Sentiment Around Loss-Making Pluristem Therapeutics Inc. (NASDAQ:PSTI)

Pluristem Therapeutics Inc. to Present Initial Results from its Phase I HCT Study

Earnings beat expectations

Insider recently bought US$184k worth of stock

Pluristem Announces Clearance to Move Forward with Enrollment for Cohort II in an Investigator-Led Phase I/II Chronic Graft vs Host Disease Study

Pluristem Expands its Phase II COVID-19 European Clinical Trial to Israel

Abu Dhabi Stem Cells Center and Pluristem Unveil Joint Projects At Malta Conferences Foundation Online Event

Insider recently bought US$97k worth of stock

Full year earnings released - US$1.60 loss per share

New 90-day high - US$11.48

New 90-day high - US$11.04

CEO報酬分析

CEO（最高経営責任者

在職期間

マネジメント基準チェック /14